1. ALLA AKTIER
  2. NYHETER
  3. SENZIME

Senzime

Nyheter Senzime Nyheter alla bolag
Affiliate
Courtagefri handel på Nordnet till sista juni 2027! Har du inget konto på Nordnet så är det verkligen läge att skaffa ett. Just nu får nya kunder courtagefri handel till sista juni 2027. Läs mer om erbjudandet och skapa ditt konto här
Erbjudandet gäller nya kunder och omfattar handel via Nordnets app eller hemsida i nordiska aktier, ETF:er, teckningsrätter och teckningsoptioner. För fullständiga villkor se nordnet.se/jubileum. Kom ihåg att investeringar alltid innebär en risk.

Invitation to Senzime's investor event

Senzime AB (publ) invites investors, financial analysts and media to a digital investor event on November 15, 2022, in the afternoon.

The purpose is to give an update of the strategy following the acquisition of Respiratory Motion, describe the market opportunities following the upcoming clinical guidelines in the US and Europe that support Senzime’s solutions, and provide long-term financial targets.

Presentations will be held by:

  • Pia Renaudin, CEO of Senzime
  • Sorin J. Brull, Professor, board member of Senzime AB and the innovator of TetraGraph
  • Kay Krüger, business manager of the recently acquired ExSpiron business who will present the latest updates on market development in Europe and the US

Presentations will be held in English and followed by a Q&A session.

Date and time
Tuesday November 15, 2022, at 13:00-15:00 CET.

More information and a link to the event will be shared in the beginning of November.

For further information, please contact:

Pia Renaudin, CEO of Senzime AB
Phone: +46 (0) 70-813 34 17, email: pia.renaudin@senzime.com

About Senzime

Senzime is a Swedish medical device company that develops, manufactures, and markets CE- and FDA-cleared patient monitoring systems. Senzime’s employees worldwide are committed to the vision of a world without anesthesia- and respiratory-related complications. The company markets an innovative portfolio of solutions, including the TetraGraph® and ExSpiron® 2Xi for real-time monitoring of neuromuscular and respiratory functions, typically under and after surgery. The goal is to help eliminate in-hospital complications, and radically reduce health care costs related to surgical and high acuity procedures.

Senzime targets a market opportunity valued more than SEK 40 billion per year, and operates with sales teams in the world’s leading markets. The company’s shares are listed on Nasdaq Stockholm Main Market (SEZI). More information is available at senzime.com.

Attachments

Invitation to Senzime's investor event

Datum 2022-10-25, kl 10:00
Källa MFN
Bifogade filer
Invitation to Senzime's investor event